Log In via Athens
Pediatric Only |
Images & Videos Only
Updates: Goodman & Gilman's The Pharmacological Basis of Therapeutics
6/22/2012: 2011 In Review: New and Noteworthy FDA Approvals Part 2 – Also Noteworthy
Chief of Pharmacy, Jonathan M. Wainwright Memorial VA Medical Center, Clinical Assistant Professor, UW School of Pharmacy
ambrisentan; antitussive agents; bevacizumab; drotrecogin alfa; drug approval; erythropoiesis-stimulating agents; everolimus; meningococcal vaccines; terbutaline; therapeutic drug monitoring; topiramate; united states food and drug administration; varicella-zoster vaccines.
See Summary Table
"The FDA approved 33 drugs and biologics of note in 2011. Most are pharmacologically similar to others already marketed (see Table 2). Among the remainder are 18 "first-in-class" agents for acute coronary syndrome, angioedema, chronic obstructive pulmonary disease, congenital factor XIII deficiency, depression, head lice, hepatitis C infection, lupus, lymphoma, melanoma, myelofibrosis, prostate cancer, seizures, diagnosis of Parkinsonian syndromes, and vaccination of military personnel against adenovirus (see part 1 of this series). Fourteen of the new drug approvals in 2011 were granted orphan drug status for rare diseases (see Table 2, Table 3, and part 1 of this series). Two of the new drugs (crizotinib for non-small cell lung cancer and vemurafenib for melanoma) were approved in conjunction with diagnostic genetic tests and represent a breakthrough in the field of personalized medicine.
In addition, one new approval, HEMACORD is the first cord blood therapy approved in the US.
The content above is only an excerpt. For full access, log into an existing user account below,
an annual subscription, or
a short-term subscription to the complete website.
Subscriber Log In:
Forgot your Username/Password?
Copyright © McGraw-Hill Global Education Holdings, LLC. All rights reserved.
. Any use is subject to the
Your IP address is 22.214.171.124